16 / 48
Clinical profile of NSCLC with ALK fusion
•
EML4–ALK fusion in 3–7% NSCLC non-squamous (study population; detection
technique)
•
Adenocarcinoma
(43% -56% signet ring cell patern, 56% chribiform variant, 52%
acinar histology, 100% TTF1 +)
•
Never/light smoker
•
Younger median age
Ejemplo: Lung Cancer Mutation Consortium Analysis of Adenocarcinomas
N=901
ALK-positivo
(n=75)
ALK-negativo
(n=826)
p
Edad media
52 yr
60 yr
<0.001
No fumadores
61%
31%
0.001
Paquetes año para exfumadores/fumadores
17
40
0.003
Metástasis hepáticas
23%
10%
0.004
Garber K. J Natl Cancer Inst 2010;102:672–5;
Rodig SJ, et al. Clin Cancer Res 2009;15:5216–23
Shaw AT, et al. J Clin Oncol 2009;27:4247–53;
Varella-Garcia M, et al. J Thorac Oncol 2011;6(6 Suppl 2):S290 (Abstract O05.01);
Varella-Garcia M, et al. J Clin Oncol 2012;30(Suppl)